Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts
暂无分享,去创建一个
[1] P H Watson,et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.
[2] A. Harris,et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Steve Horvath,et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] P. Fraker,et al. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.
[5] H. Minn,et al. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer , 2009, British Journal of Cancer.
[6] Michael M. Schmidt,et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.
[7] C. Ling,et al. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. , 2008, Cancer research.
[8] K. Fujimori,et al. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. , 1989, Cancer research.
[9] A. Harris,et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. , 2001, Cancer research.
[10] A. Harris,et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] P. Bunn,et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.
[12] Seppo Parkkila,et al. BMC Cancer BioMed Central Research article Carbonic anhydrase IX in oligodendroglial brain tumors , 2008 .
[13] R. Figlin,et al. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] Donna Richardson,et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Dvorak,et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.
[16] C. Ling,et al. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. , 2007, Cancer research.
[17] J. Pastorek,et al. Biodistribution and pharmacokinetics of 125I‐labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma , 2003, International journal of cancer.
[18] A. Harris,et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[20] J. Weinstein,et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.
[21] T. Yokota,et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.
[22] M. Flentje,et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[23] A. Harris,et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. , 2001, Cancer research.
[24] K. Haustermans,et al. Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas , 2006, Annals of surgery.
[25] A. Harris,et al. Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumour: Hypoxia, Survival Pathway and Therapy Target , 2004, Cell cycle.
[26] J. Schalken,et al. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. , 2004, Oncogene.
[27] A. Scott,et al. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. , 2011, Urologic oncology.
[28] J. Vermorken,et al. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. , 2007, The oncologist.
[29] S. Batra,et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. , 2002, Current opinion in biotechnology.
[30] S. Parkkila,et al. Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours. , 2005, World journal of gastroenterology.
[31] J. Humm,et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.
[32] Charles C Wykoff,et al. DEC1 (STRA13) protein expression relates to hypoxia‐ inducible factor 1‐alpha and carbonic anhydrase‐9 overexpression in non‐small cell lung cancer , 2003, The Journal of pathology.
[33] J. Pastorek,et al. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. , 2001, Journal of hepatology.
[34] N. James,et al. Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. , 2004, Oncology Report.
[35] N. Bander,et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. , 2000, Cancer research.
[36] F. Buchegger,et al. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice , 1983, The Journal of experimental medicine.
[37] W. Sly,et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. , 2001, The American journal of pathology.
[38] J. Pastorek,et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. , 1997, Gastroenterology.
[39] D. Solit,et al. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. , 2004, Methods in enzymology.